Antitauon Apr 2026

Using antibodies to bind to extracellular tau species, preventing them from being taken up by healthy neighboring neurons.

Small Phase I studies have shown ASOs are safe and can reduce aggregated tau. Current Challenges and Clinical Status antitauon

While many antitauon therapies have reached clinical trials, results have been mixed: Using antibodies to bind to extracellular tau species,

The concept of "tauons" arises from the observation that misfolded tau protein isoforms can propagate through the brain in a characteristic pattern, similar to prions, driving the progression of conditions like Alzheimer's disease. Antitauon therapies aim to intervene in this process through several key mechanisms: similar to prions